α-Zearalanol, a phytoestrogen for cardiovascular therapy
- 67 Downloads
Estrogen replacement therapy (ERT) is one of the most challenging issues women and their physicians have to face. Clinical and epidemiological studies have provided conflicting data regarding the cardiovascular benefit versus risk in women using ERT. Although ERT may improve several risk factors of coronary heart disease such as favorable changes in lipid profile, an associated increased incidence of uterine and breast tumors has jeopardized the clinical use of ERT. We reported here that the phytoestrogen α-zearalanol is effective against atherosclerotic development without overt growth-promoting effects in the uterus compared to estrogen. These results suggest clinical potential of this phytoestrogen as a “safe estrogen” with less risk of tumorogenesis.
Key WordsPhytoestrogen estrogen cardiovascular atherosclerosis uterine growth
Unable to display preview. Download preview PDF.
- 6.Dai, S., Duan, J., Lu, Y., et al. (2004). Endocrine 25, xxx-xxx.Google Scholar
- 8.Li, J. L., Zhu, T. X., Zhang, H., et al. (1980). Acta Agricul. Universitatis Pekinensis 1, 13–27.Google Scholar
- 9.Fu, F. Y. (1991). Acta Agricul. Universitatis Pekinensis 17, 117–118.Google Scholar
- 10.Dai, S., Duan, J., Lu, Y., et al. (2002). J. Mol. Cell. Cardiol. 34, A3.Google Scholar